Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Aptiom (eslicarbazepine acetate) is indicated for the treatment of partial-onset seizures in patients 4 years of age and older.
• This summary is based on the review of eight systematic review(s)/meta-analysis(es). ^[1-8]
• Eslicarbazepine acetate (ESL) was generally effective in reducing seizure frequency and achieving a ≥50% responder rate, particularly in adults with focal epilepsy. However, it was less effective compared to cenobamate (CNB) and brivaracetam in achieving seizure freedom.
• ESL showed dose-dependent effectiveness in adults, with higher effectiveness observed at 800 mg/day, but it did not significantly improve outcomes in children, where higher dropout rates and lower effectiveness were noted compared to other antiseizure medications.
• ESL was associated with fewer adverse events compared to placebo but had higher treatment-emergent adverse events (TEAEs) and dropout rates due to adverse events compared to other antiseizure medications (ASMs) such as brivaracetam and lacosamide.
• In children, ESL showed higher dropout rates due to adverse events compared to other ASMs, and at a higher dose (1200 mg/d), it significantly increased the risk of severe adverse events.
• There is no population types or subgroups information available in the reviewed studies.